hematology

Emavusertib Unleashed: Key Takeaways & FDA’s New Direction

July 24, 2023 hematology, Oncology by Mellalta Meets Analyst Leave a Comment

The medical community eagerly anticipates Curis’ next steps after their revolutionary drug, Emavusertib (CA-4948), experienced a significant milestone: the lifting of the FDA’s clinical hold. Here’s an in-depth look at what this development means for […]

Watch 2023 Actinium Pioneering Strategies_Mellalta Meets

Revealed: Actinium KOLs Engagement and Pioneering Strategies for Iomab-B and Actimab-A

July 20, 2023 hematology, Oncology by Mellalta Meets Analyst Leave a Comment

As Actinium forges ahead with its transformative therapies, including Iomab-B and Actimab-A, its strategic approach extends beyond clinical trials and regulatory milestones. Actinium’s presentation of six abstracts at the Society for Nuclear Medicine and Molecular […]

Cart

Emavusertib Unleashed: Key Takeaways & FDA’s New Direction

Revealed: Actinium KOLs Engagement and Pioneering Strategies for Iomab-B and Actimab-A

Search articles

Social

Latest Cast Studies

Artificial Intelligence Diagnostic Tool–Due Diligence for Collaboration

Robot-Assisted Surgical System–MedTech Market Intelligence

Anti-Infective–Market Access Strategies

Upcoming Events

How Nanobiotix’s Breakthrough NBTXR3 is Poised to Radically Transform the LA-HNSCC Landscape?

Xevinapant Takes the Lead: Merck’s Bold Market Strategies to Outshine Rivals in LA-HNSCC !